Skip to Content

Taliglucerase Alfa Dosage

Medically reviewed by Drugs.com. Last updated on Nov 11, 2019.

Applies to the following strengths: 200 units

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Gaucher Disease

Treatment-naive:
-Initial dose: 60 units/kg IV every other week

Conversion from imiglucerase:
-For patients on a stable dose of imiglucerase: Begin at same units/kg dose IV every other week

Dose adjustments should be based on individual's therapeutic goals
-A clinical study evaluated doses ranging from 9.5 to 60 units/kg IV every other week

Comments:
-Administer as an IV infusion over 60 to 120 minutes every other week; in adult patients, an initial infusion rate of 1.2 mL/minute should be used.
-After tolerability to infusion is established, the infusion rate may be increased, but should not exceed the maximum recommended infusion rate of 2.2 mL/minute; infusion should be delivered over a minimum or 60 minutes.

Use: For long-term enzyme replacement therapy (ERT) for patients with confirmed diagnosis of type 1 Gaucher disease

Usual Pediatric Dose for Gaucher Disease

4 years or older:
Treatment-naive:
-Initial dose: 60 units/kg IV every other week

Conversion from imiglucerase:
-For patients on a stable dose of imiglucerase: Begin at same units/kg dose IV every other week

Dose adjustments should be based on individual's therapeutic goals
-A clinical study evaluated doses ranging from 9.5 to 60 units/kg IV every other week

Comments:
-Administer as an IV infusion over 60 to 120 minutes every other week; in adult patients, an initial infusion rate of 1.2 mL/minute should be used.
-After tolerability to infusion is established, the infusion rate may be increased, but should not exceed the maximum recommended infusion rate of 2.2 mL/minute; infusion should be delivered over a minimum or 60 minutes.

Use: For long-term enzyme replacement therapy (ERT) for patients 4 years or older with a confirmed diagnosis of type 1 Gaucher disease

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
-None

Safety and efficacy have not been established in patients younger than 4 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:
-For IV infusion over a minimum of 60 minutes every other week
-Due to the potential for anaphylaxis, appropriate medical support should be readily available during administration

Adults:
-Initial infusion rate: 1.2 mL/minute
-Once tolerability is established, may increase rate
-Maximum infusion rate: 2 mL/minute
Pediatrics:
-Initial infusion rate: 1 mL/minute
-Once tolerability is established, may increase
Maximum infusion rate: 2 mL/min

Reconstitution/preparation techniques:
-Should be prepared under the supervision of a healthcare professional; consult product labeling for additional instructions
-Reconstitute each vial with 5.1 mL of Sterile Water for Injection to yield a concentration of 40 units/mL and an extractable volume of 5 mL; upon reconstitution, mix vials gently, do not shake
-Further dilute with 0.9% sodium chloride to a final volume of 100 or 200 mL
-Following reconstitution and dilution, administer via IV infusion; filter through an in-line low-protein-binding 0.2 micrometer filter

Storage Requirements:
-Store in refrigerator at 2C to 8C (36F to 46F); protect from light
-Once vials removed from refrigerator, must be used reconstituted within 24 hours; do not heat or microwave.
-Reconstituted product: May store for up to 24 hours at 2C to 8C (36F to 46F) when protected from light or up to 4 hours at 20C to 25C (68F to 77F) when not protected from light
-Diluted product: May store for up to 24 hours at 2C to 8C (36F to 46F) when protected from light
-Storage of reconstituted and diluted products should not exceed 24 hours total
-Do not freeze

Monitoring:
-Hypersensitivity: Signs/symptoms of allergic reactions and/or infusion-related reactions (during and after infusion)

Patient Advice:
-Patients and caregivers should understand that infusion-related and hypersensitivity reactions including anaphylaxis may occur with therapy.
-Patients and caregivers should be informed of the signs and symptoms of anaphylaxis and hypersensitivity reactions and should be instructed to seek medical care should signs and symptoms occur.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide